Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Slides:

Advertisements

Similar presentations

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Advertisements

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Single-Dose Azithromycin versus Penicillin G Benzathine for the Treatment of Early Syphilis Jay Gargus, Department of Biological and Environmental Sciences,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID July 2, 2013 HIV Vaccine and Future Strategies.

Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Supplementary Table 1 Table S1. Population frequency of HLA -A, -B and -C alleles. Rare alleles (frequency < 0.5%) are highlighted by a grey background.

Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.

RV 144: The Thai Phase III Trial and Development of a Globally-Effective, Multi-Clade HIV Vaccine HIV Vaccine: Quo Vadis AIDS July 2010 Dr. Merlin.

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee Nathan.

MHRP  The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army or the Department of Defense.

Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Immunogenicity of 13-Valent Pneumococcal Conjugate.

This PowerPoint document contains the images that you requested.

This PowerPoint document contains the images that you requested.

This PowerPoint document contains the images that you requested.

This PowerPoint document contains the images that you requested.

This PowerPoint document contains the images that you requested.

From: Rotarix: A Rotavirus Vaccine for the World

HIV Vaccine Trials Network

Understanding EMPA-REG OUTCOME

Understanding EMPA-REG OUTCOME

Volume 3, Issue 9, Pages e421-e430 (September 2016)

Figure 1 Periprocedural myonecrosis and myocardial infarction after left main coronary artery revascularization with ... Figure 1 Periprocedural myonecrosis.

Figure 1 Study flow diagram and definition of clinical response

Figure 1 Multivariable-adjusted predictors of PAC

FIGURE 1 Flow chart of patient enrollment and exclusion

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

bDMARD: biologic DMARD.

Fig. 1 MRI aspect of an osteitis of the left acetabulum at baseline (A), 3 months (B), 1 year (C) and 2 years later, ... Fig. 1 MRI aspect of an osteitis.

Fig. 1 Flow chart of included patients for analyses

Fig. 1 Flow chart for selection of study subjects

Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

The independent additive value of total greyscale + power Doppler synovitis ... The independent additive value of total greyscale + power Doppler synovitis.

Figure 1. Observed mean (SD) micafungin plasma concentrations.

Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM.

The figure shows the fraction of ...

Assessed for eligibility N = 15593

Enrolled and randomized Per-protocol efficacy population

Figure 1. Kaplan Meier curves showing crude product limit survival estimates and 95% confidence intervals for time to ... Figure 1. Kaplan Meier curves.

Figure 1 ABCDE of primary prevention.2

Figure 1. Overall response rates in wild-type versus RAS and RAS/BRAF mutations detected by nanofluidic digital PCR ... Figure 1. Overall response rates.

Figure 1. Kaplan–Meier curves showing the impact of the different pretreatment HIV-1 drug resistance categories on the ... Figure 1. Kaplan–Meier curves.

Figure 1. Estimated weight functions (dotted-dashed lines) and pointwise 95% bootstrap confidence intervals (shaded ... Figure 1. Estimated weight functions.

Presentation transcript:

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation, text, pictures, graphics and other files and the selection and arrangement thereof are copyrighted materials of Ovid or its licensors, all rights reserved. Except for the Authorized Use specified above, you may not copy, modify or distribute any of the Online Service materials. You may not "mirror" any material contained on this Online Service on any other server. Any unauthorized use of any material contained on this Online Service may violate copyright laws, trademark laws, the laws of privacy and publicity and communications regulations and statutes.

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 2 Figure 1 Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. Rerks-Ngarm, Supachai; Pitisuttithum, Punnee; Nitayaphan, Sorachai; Kaewkungwal, Jaranit; Chiu, Joseph; Paris, Robert; Premsri, Nakorn; Namwat, Chawetsan; de Souza, Mark; Adams, Elizabeth; Benenson, Michael; Gurunathan, Sanjay; Tartaglia, Jim; McNeil, John; Francis, Donald; Stablein, Donald; Birx, Deborah; Chunsuttiwat, Supamit; Khamboonruang, Chirasak; Thongcharoen, Prasert; Robb, Merlin; Michael, Nelson; Kunasol, Prayura; Kim, Jerome New England Journal of Medicine. 361(23): , December 3, Figure 1. Enrollment and Outcomes.During the course of the study, there were 15 HIV-1 infections in the vaccine group and 24 in the placebo group that were excluded from the final analysis. This left 12,542 volunteers (6176 in the vaccine group and 6366 in the placebo group) who received all four doses of vaccine within the prespecified time period, who were not excluded for the other reasons, and who did not have HIV-1 infection at visit 7 (per-protocol population).

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 3 Table 1 Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. Rerks-Ngarm, Supachai; Pitisuttithum, Punnee; Nitayaphan, Sorachai; Kaewkungwal, Jaranit; Chiu, Joseph; Paris, Robert; Premsri, Nakorn; Namwat, Chawetsan; de Souza, Mark; Adams, Elizabeth; Benenson, Michael; Gurunathan, Sanjay; Tartaglia, Jim; McNeil, John; Francis, Donald; Stablein, Donald; Birx, Deborah; Chunsuttiwat, Supamit; Khamboonruang, Chirasak; Thongcharoen, Prasert; Robb, Merlin; Michael, Nelson; Kunasol, Prayura; Kim, Jerome New England Journal of Medicine. 361(23): , December 3, Table 1. Baseline Characteristics of the Subjects (Modified Intention-to-Treat Population).

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 4 Figure 2 Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. Rerks-Ngarm, Supachai; Pitisuttithum, Punnee; Nitayaphan, Sorachai; Kaewkungwal, Jaranit; Chiu, Joseph; Paris, Robert; Premsri, Nakorn; Namwat, Chawetsan; de Souza, Mark; Adams, Elizabeth; Benenson, Michael; Gurunathan, Sanjay; Tartaglia, Jim; McNeil, John; Francis, Donald; Stablein, Donald; Birx, Deborah; Chunsuttiwat, Supamit; Khamboonruang, Chirasak; Thongcharoen, Prasert; Robb, Merlin; Michael, Nelson; Kunasol, Prayura; Kim, Jerome New England Journal of Medicine. 361(23): , December 3, Figure 2. Kaplan-Meier Cumulative Rates of Infection, According to Type of Analysis.The vaccination regimen was completed approximately 6 months after the first dose was administered. In the intention-to-treat analysis involving 16,402 subjects, the vaccine efficacy was 26.4% (95% confidence interval [CI], -4.0 to 47.9; P=0.08) (Panel A). In the per-protocol analysis involving 12,542 subjects, the vaccine efficacy was 26.2% (95% CI, to 51.9; P=0.16) (Panel B). In the modified intention-to-treat analysis involving 16,395 subjects (excluding 7 subjects who were found to have had HIV infection at baseline), the vaccine efficacy was 31.2% (95% CI, 1.1 to 51.2; P=0.04) (Panel C).

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 5 Table 2 Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. Rerks-Ngarm, Supachai; Pitisuttithum, Punnee; Nitayaphan, Sorachai; Kaewkungwal, Jaranit; Chiu, Joseph; Paris, Robert; Premsri, Nakorn; Namwat, Chawetsan; de Souza, Mark; Adams, Elizabeth; Benenson, Michael; Gurunathan, Sanjay; Tartaglia, Jim; McNeil, John; Francis, Donald; Stablein, Donald; Birx, Deborah; Chunsuttiwat, Supamit; Khamboonruang, Chirasak; Thongcharoen, Prasert; Robb, Merlin; Michael, Nelson; Kunasol, Prayura; Kim, Jerome New England Journal of Medicine. 361(23): , December 3, Table 2. Rate of HIV Infection and Vaccine Efficacy, According to Selected Baseline Variables (Modified Intention-to-Treat Population).

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 6 Figure 3 Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. Rerks-Ngarm, Supachai; Pitisuttithum, Punnee; Nitayaphan, Sorachai; Kaewkungwal, Jaranit; Chiu, Joseph; Paris, Robert; Premsri, Nakorn; Namwat, Chawetsan; de Souza, Mark; Adams, Elizabeth; Benenson, Michael; Gurunathan, Sanjay; Tartaglia, Jim; McNeil, John; Francis, Donald; Stablein, Donald; Birx, Deborah; Chunsuttiwat, Supamit; Khamboonruang, Chirasak; Thongcharoen, Prasert; Robb, Merlin; Michael, Nelson; Kunasol, Prayura; Kim, Jerome New England Journal of Medicine. 361(23): , December 3, Figure 3. Viral Loads in Subjects with Early HIV-1 Infection.The receipt of vaccine did not have a significant effect on the viral load in subjects who were found to have early HIV-1 infection. On the left are the mean log10 viral loads at three visits during a 6-week period for subjects who were included in the intention-to-treat analysis. The data points at the right show the distribution of viral loads in the vaccine group (mean, 4.36 log10 copies per milliliter) and the placebo group (mean, 4.21 log10 copies per milliliter) (P=0.09). There was no significant between-group difference in viral load in either the per-protocol analysis (P=0.47) or the modified intention-to-treat analysis (P=0.24).

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 7 Table 3 Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. Rerks-Ngarm, Supachai; Pitisuttithum, Punnee; Nitayaphan, Sorachai; Kaewkungwal, Jaranit; Chiu, Joseph; Paris, Robert; Premsri, Nakorn; Namwat, Chawetsan; de Souza, Mark; Adams, Elizabeth; Benenson, Michael; Gurunathan, Sanjay; Tartaglia, Jim; McNeil, John; Francis, Donald; Stablein, Donald; Birx, Deborah; Chunsuttiwat, Supamit; Khamboonruang, Chirasak; Thongcharoen, Prasert; Robb, Merlin; Michael, Nelson; Kunasol, Prayura; Kim, Jerome New England Journal of Medicine. 361(23): , December 3, Table 3. Immunogenicity Analyses at Baseline and 12 Months.